Immune checkpoint inhibitor therapies (ICI) that target the PD‐1/PD‐L1 axis have become first-line treatment options as monotherapy or in combination with chemotherapy for patients with stage IV NSCLC and shown significantly improved clinical outcomes in some patients (3). Here, CD274 is linked to non-small cell lung carcinoma.